Insider Trades147 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Sell | AORT | Andrew M Green | SVP, Regulatory and Quality | 616 | $28.55 | $1.3B | -44.52% | +39.72% | $17.6K | -1.02% | — | Buy Now |
| Aug 14, 2026 | Sell | AORT | Lance A Berry | EVP, COO, CFO & Treasurer | 715 | $28.55 | $1.3B | -44.52% | +39.72% | $20.4K | -0.34% | — | Buy Now |
| Aug 12, 2026 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 977 | $28.49 | $1.3B | -44.52% | +39.72% | $27.8K | -0.53% | — | Buy Now |
| Jun 11, 2026 | Sell | AORT | Andrew M Green | SVP, Regulatory and Quality | 88,002 | $17.04 | $1.3B | -44.52% | +39.72% | $1.5M | +0.00% | — | Buy Now |
| Mar 3, 2026 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 901 | $37.78 | $1.3B | -44.52% | +39.72% | $34.0K | -0.64% | — | Buy Now |
| Mar 3, 2026 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 2,149 | $37.78 | $1.3B | -44.52% | +39.72% | $81.2K | -3.45% | — | Buy Now |
| Mar 3, 2026 | Sell | AORT | John E Davis | Chief Commercial Officer | 4,573 | $37.78 | $1.3B | -44.52% | +39.72% | $172.7K | -1.94% | — | Buy Now |
| Mar 3, 2026 | Sell | AORT | Lance A Berry | EVP, COO, CFO & Treasurer | 6,316 | $37.78 | $1.3B | -44.52% | +39.72% | $238.6K | -2.91% | — | Buy Now |
| Mar 3, 2026 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 12,805 | $37.93 | $1.3B | -44.52% | +39.72% | $485.7K | -3.27% | — | Buy Now |
| Mar 3, 2026 | Sell | AORT | James P Mackin | President & CEO | 17,887 | $37.78 | $1.3B | -44.52% | +39.72% | $675.7K | -1.85% | — | Buy Now |
| Mar 2, 2026 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 641 | $38.02 | $1.3B | -44.52% | +39.72% | $24.4K | -0.48% | — | Buy Now |
| Mar 2, 2026 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 1,513 | $38.02 | $1.3B | -44.52% | +39.72% | $57.5K | -3.61% | — | Buy Now |
| Mar 2, 2026 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 2,183 | $38.02 | $1.3B | -44.52% | +39.72% | $83.0K | -1.27% | — | Buy Now |
| Mar 2, 2026 | Sell | AORT | John E Davis | Chief Commercial Officer | 2,784 | $38.02 | $1.3B | -44.52% | +39.72% | $105.9K | -1.33% | — | Buy Now |
| Mar 2, 2026 | Sell | AORT | Lance A Berry | EVP, COO, CFO & Treasurer | 5,178 | $38.02 | $1.3B | -44.52% | +39.72% | $196.9K | -2.85% | — | Buy Now |
| Mar 2, 2026 | Sell | AORT | James P Mackin | President & CEO | 14,911 | $38.02 | $1.3B | -44.52% | +39.72% | $567.0K | -1.73% | — | Buy Now |
| Feb 23, 2026 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 2,561 | $36.97 | $1.3B | -44.52% | +39.72% | $94.7K | -0.99% | — | Buy Now |
| Feb 23, 2026 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 3,682 | $36.94 | $1.3B | -44.52% | +39.72% | $136.0K | -4.15% | — | Buy Now |
| Feb 23, 2026 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 4,747 | $36.92 | $1.3B | -44.52% | +39.72% | $175.3K | -1.53% | — | Buy Now |
| Feb 23, 2026 | Sell | AORT | John E Davis | Chief Commercial Officer | 5,848 | $36.92 | $1.3B | -44.52% | +39.72% | $215.9K | -1.52% | — | Buy Now |
| Feb 23, 2026 | Sell | AORT | Lance A Berry | EVP, COO, CFO & Treasurer | 9,466 | $36.69 | $1.3B | -44.52% | +39.72% | $347.3K | -3.14% | — | Buy Now |
| Feb 23, 2026 | Sell | AORT | James P Mackin | President & CEO | 34,898 | $36.83 | $1.3B | -44.52% | +39.72% | $1.3M | -2.21% | — | Buy Now |
| Dec 15, 2025 | Sell | AORT | John E Davis | Chief Commercial Officer | 5,000 | $45.11 | $1.3B | -44.52% | +39.72% | $225.6K | -2.51% | — | Buy Now |
| Dec 8, 2025 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 4,572 | $44.42 | $1.3B | -44.52% | +39.72% | $203.1K | -3.40% | — | Buy Now |
| Dec 3, 2025 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 7,315 | $45.30 | $1.3B | -44.52% | +39.72% | $331.4K | -2.25% | — | Buy Now |
| Dec 3, 2025 | Sell | AORT | James P Mackin | President & CEO | 61,842 | $37.54 | $1.3B | -44.52% | +39.72% | $2.3M | +0.00% | — | Buy Now |
| Dec 2, 2025 | Sell | AORT | James P Mackin | President & CEO | 61,842 | $37.59 | $1.3B | -44.52% | +39.72% | $2.3M | +0.00% | — | Buy Now |
| Dec 1, 2025 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 750 | $45.83 | $1.3B | -44.52% | +39.72% | $34.4K | -0.55% | — | Buy Now |
| Nov 21, 2025 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 94,752 | $29.62 | $1.3B | -44.52% | +39.72% | $2.8M | +0.00% | — | Buy Now |
| Nov 20, 2025 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 18,664 | $38.97 | $1.3B | -44.52% | +39.72% | $727.3K | -4.15% | — | Buy Now |
| Nov 17, 2025 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 6,000 | $45.73 | $1.3B | -44.52% | +39.72% | $274.4K | -4.24% | — | Buy Now |
| Nov 14, 2025 | Sell | AORT | John E Davis | Chief Commercial Officer | 25,574 | $37.27 | $1.3B | -44.52% | +39.72% | $953.1K | +0.00% | — | Buy Now |
| Nov 14, 2025 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 25,574 | $37.35 | $1.3B | -44.52% | +39.72% | $955.3K | +0.00% | — | Buy Now |
| Nov 13, 2025 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 3,482 | $45.86 | $1.3B | -44.52% | +39.72% | $159.7K | -2.40% | — | Buy Now |
| Nov 13, 2025 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 4,993 | $45.86 | $1.3B | -44.52% | +39.72% | $229.0K | -8.10% | — | Buy Now |
| Nov 13, 2025 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 5,761 | $45.86 | $1.3B | -44.52% | +39.72% | $264.2K | -3.41% | — | Buy Now |
| Nov 13, 2025 | Sell | AORT | John E Davis | Chief Commercial Officer | 6,563 | $45.86 | $1.3B | -44.52% | +39.72% | $301.0K | -3.20% | — | Buy Now |
| Nov 13, 2025 | Sell | AORT | James P Mackin | President & CEO | 34,210 | $45.86 | $1.3B | -44.52% | +39.72% | $1.6M | -4.10% | — | Buy Now |
| Nov 10, 2025 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 1,789 | $44.62 | $1.3B | -44.52% | +39.72% | $79.8K | -1.22% | — | Buy Now |
| Nov 10, 2025 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 2,566 | $44.62 | $1.3B | -44.52% | +39.72% | $114.5K | -4.00% | — | Buy Now |
| Nov 10, 2025 | Sell | AORT | John E Davis | Chief Commercial Officer | 3,373 | $44.62 | $1.3B | -44.52% | +39.72% | $150.5K | -1.62% | — | Buy Now |
| Nov 10, 2025 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 22,960 | $30.67 | $1.3B | -44.52% | +39.72% | $704.2K | -0.57% | — | Buy Now |
| Nov 10, 2025 | Sell | AORT | James P Mackin | President & CEO | 17,580 | $44.62 | $1.3B | -44.52% | +39.72% | $784.4K | -2.06% | — | Buy Now |
| Aug 27, 2025 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 36,400 | $27.53 | $1.3B | -44.52% | +39.72% | $1.0M | +0.00% | — | Buy Now |
| Aug 25, 2025 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 20,000 | $27.70 | $1.3B | -44.52% | +39.72% | $554.0K | +0.00% | — | Buy Now |
| Aug 15, 2025 | Sell | AORT | James P Mackin | President & CEO | 12,500 | $42.32 | $1.3B | -44.52% | +39.72% | $529.0K | -1.44% | — | Buy Now |
| Aug 12, 2025 | Sell | AORT | John E Davis | Chief Commercial Officer | 21,604 | $34.96 | $1.3B | -44.52% | +39.72% | $755.2K | +0.00% | — | Buy Now |
| Aug 12, 2025 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 40,331 | $35.95 | $1.3B | -44.52% | +39.72% | $1.5M | -1.15% | — | Buy Now |
| Aug 8, 2025 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 15,984 | $34.05 | $1.3B | -44.52% | +39.72% | $544.3K | +0.00% | — | Buy Now |
| Jun 17, 2025 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 15,000 | $29.50 | $1.3B | -44.52% | +39.72% | $442.5K | -10.37% | — | Buy Now |
| Jun 13, 2025 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 26,132 | $28.44 | $1.3B | -44.52% | +39.72% | $743.1K | -6.91% | — | Buy Now |
| May 27, 2025 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 8,748 | $29.00 | $1.3B | -44.52% | +39.72% | $253.7K | -4.67% | — | Buy Now |
| May 21, 2025 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 9,926 | $29.00 | $1.3B | -44.52% | +39.72% | $287.9K | -5.03% | — | Buy Now |
| May 9, 2025 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 10,548 | $29.13 | $1.3B | -44.52% | +39.72% | $307.3K | -4.67% | — | Buy Now |
| Mar 11, 2025 | Buy | AORT | John E Davis | Chief Commercial Officer | 31,010 | $22.55 | $1.3B | -44.52% | +39.72% | $699.4K | +0.19% | — | Buy Now |
| Mar 11, 2025 | Buy | AORT | Jean F Holloway | SVP, General Counsel | 37,112 | $22.55 | $1.3B | -44.52% | +39.72% | $836.9K | +0.26% | — | Buy Now |
| Mar 6, 2025 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 1,048 | $24.80 | $1.3B | -44.52% | +39.72% | $26.0K | -0.71% | — | Buy Now |
| Mar 6, 2025 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 1,603 | $24.80 | $1.3B | -44.52% | +39.72% | $39.8K | -1.36% | — | Buy Now |
| Mar 6, 2025 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 2,124 | $24.80 | $1.3B | -44.52% | +39.72% | $52.7K | -1.07% | — | Buy Now |
| Mar 6, 2025 | Sell | AORT | John E Davis | Chief Commercial Officer | 2,618 | $24.80 | $1.3B | -44.52% | +39.72% | $64.9K | -1.24% | — | Buy Now |
| Mar 6, 2025 | Sell | AORT | Lance A Berry | Executive VP, CFO | 4,909 | $24.80 | $1.3B | -44.52% | +39.72% | $121.8K | -3.10% | — | Buy Now |
| Mar 6, 2025 | Sell | AORT | James P Mackin | President & CEO | 164,054 | $23.29 | $1.3B | -44.52% | +39.72% | $3.8M | -0.48% | — | Buy Now |
| Mar 5, 2025 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 472 | $25.29 | $1.3B | -44.52% | +39.72% | $11.9K | -0.27% | — | Buy Now |
| Feb 24, 2025 | Sell | AORT | Lance A Berry | Executive VP, CFO | 3,259 | $27.31 | $1.3B | -44.52% | +39.72% | $89.0K | -4.12% | — | Buy Now |
| Feb 24, 2025 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 3,323 | $27.31 | $1.3B | -44.52% | +39.72% | $90.7K | -0.63% | — | Buy Now |
| Feb 24, 2025 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 4,687 | $27.31 | $1.3B | -44.52% | +39.72% | $128.0K | -1.42% | — | Buy Now |
| Feb 24, 2025 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 5,335 | $27.31 | $1.3B | -44.52% | +39.72% | $145.7K | -0.87% | — | Buy Now |
| Feb 24, 2025 | Sell | AORT | John E Davis | Chief Commercial Officer | 6,457 | $27.31 | $1.3B | -44.52% | +39.72% | $176.3K | -0.98% | — | Buy Now |
| Feb 24, 2025 | Sell | AORT | James P Mackin | President & CEO | 42,156 | $27.31 | $1.3B | -44.52% | +39.72% | $1.2M | -1.54% | — | Buy Now |
| Dec 12, 2024 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 1,100 | $29.50 | $1.3B | -44.52% | +39.72% | $32.5K | -0.81% | — | Buy Now |
| Dec 11, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 8,070 | $30.13 | $1.3B | -44.52% | +39.72% | $243.1K | -2.52% | — | Buy Now |
| Dec 6, 2024 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 4,329 | $29.66 | $1.3B | -44.52% | +39.72% | $128.4K | -3.09% | — | Buy Now |
| Dec 6, 2024 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 4,425 | $29.05 | $1.3B | -44.52% | +39.72% | $128.6K | -3.16% | — | Buy Now |
| Dec 4, 2024 | Sell | AORT | Andrew M Green | VP Regulatory | 7,618 | $30.00 | $1.3B | -44.52% | +39.72% | $228.5K | -18.53% | — | Buy Now |
| Oct 1, 2024 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 24,860 | $23.86 | $1.3B | -44.52% | +39.72% | $593.3K | +0.00% | — | Buy Now |
| Aug 26, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 3,167 | $26.55 | $1.3B | -44.52% | +39.72% | $84.1K | -1.92% | — | Buy Now |
| Aug 16, 2024 | Sell | AORT | Matthew A Getz | VP, Human Resources | 9,420 | $25.31 | $1.3B | -44.52% | +39.72% | $238.4K | -11.74% | — | Buy Now |
| Aug 15, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 2,383 | $25.76 | $1.3B | -44.52% | +39.72% | $61.4K | -1.42% | — | Buy Now |
| May 10, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 1,250 | $23.42 | $1.3B | -44.52% | +39.72% | $29.3K | -0.74% | — | Buy Now |
| May 9, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 979 | $23.79 | $1.3B | -44.52% | +39.72% | $23.3K | -0.58% | — | Buy Now |
| Mar 20, 2024 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 2,183 | $20.39 | $1.3B | -44.52% | +39.72% | $44.5K | -2.55% | — | Buy Now |
| Mar 15, 2024 | Sell | AORT | Andrew M Green | VP Regulatory | 1,462 | $20.00 | $1.3B | -44.52% | +39.72% | $29.2K | -3.43% | — | Buy Now |
| Mar 14, 2024 | Sell | AORT | Andrew M Green | VP Regulatory | 3,994 | $20.00 | $1.3B | -44.52% | +39.72% | $79.9K | -8.58% | — | Buy Now |
| Mar 12, 2024 | Sell | AORT | Matthew A Getz | VP, Human Resources | 5,000 | $19.94 | $1.3B | -44.52% | +39.72% | $99.7K | -10.30% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 1,152 | $18.72 | $1.3B | -44.52% | +39.72% | $21.6K | -0.82% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 1,152 | $18.72 | $1.3B | -44.52% | +39.72% | $21.6K | -0.82% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | Matthew A Getz | VP, Human Resources | 1,157 | $18.72 | $1.3B | -44.52% | +39.72% | $21.7K | -2.33% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | Matthew A Getz | VP, Human Resources | 1,157 | $18.72 | $1.3B | -44.52% | +39.72% | $21.7K | -2.33% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | Rochelle L. Maney | VP, Quality | 1,157 | $18.72 | $1.3B | -44.52% | +39.72% | $21.7K | -2.43% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | Rochelle L. Maney | VP, Quality | 1,157 | $18.72 | $1.3B | -44.52% | +39.72% | $21.7K | -2.42% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | Andrew M Green | VP Regulatory | 1,160 | $18.72 | $1.3B | -44.52% | +39.72% | $21.7K | -2.43% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | Andrew M Green | VP Regulatory | 1,160 | $18.72 | $1.3B | -44.52% | +39.72% | $21.7K | -2.43% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 1,506 | $18.72 | $1.3B | -44.52% | +39.72% | $28.2K | -1.73% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | John E Davis | Chief Commercial Officer | 2,022 | $18.72 | $1.3B | -44.52% | +39.72% | $37.9K | -1.21% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | John E Davis | Chief Commercial Officer | 2,022 | $18.72 | $1.3B | -44.52% | +39.72% | $37.9K | -1.21% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 2,380 | $18.72 | $1.3B | -44.52% | +39.72% | $44.6K | -1.38% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 2,380 | $18.72 | $1.3B | -44.52% | +39.72% | $44.6K | -1.38% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | James P Mackin | President & CEO | 13,996 | $18.72 | $1.3B | -44.52% | +39.72% | $262.0K | -1.95% | — | Buy Now |
| Mar 5, 2024 | Sell | AORT | James P Mackin | President & CEO | 13,996 | $18.72 | $1.3B | -44.52% | +39.72% | $262.0K | -1.94% | — | Buy Now |
| Mar 1, 2024 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 1,506 | $18.72 | $1.3B | -44.52% | +39.72% | $28.2K | -1.73% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Matthew A Getz | VP, Human Resources | 325 | $19.83 | $1.3B | -44.52% | +39.72% | $6.4K | -0.70% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 325 | $19.83 | $1.3B | -44.52% | +39.72% | $6.4K | -0.24% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Matthew A Getz | VP, Human Resources | 325 | $19.83 | $1.3B | -44.52% | +39.72% | $6.4K | -0.70% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 325 | $19.83 | $1.3B | -44.52% | +39.72% | $6.4K | -0.24% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Florian Tyrs | VP, Global Operations | 339 | $19.83 | $1.3B | -44.52% | +39.72% | $6.7K | -1.55% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Rochelle L. Maney | VP, Quality | 370 | $19.83 | $1.3B | -44.52% | +39.72% | $7.3K | -0.83% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Rochelle L. Maney | VP, Quality | 370 | $19.83 | $1.3B | -44.52% | +39.72% | $7.3K | -0.83% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Andrew M Green | VP Regulatory | 421 | $19.83 | $1.3B | -44.52% | +39.72% | $8.4K | -0.95% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Andrew M Green | VP Regulatory | 421 | $19.83 | $1.3B | -44.52% | +39.72% | $8.4K | -0.94% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 465 | $19.83 | $1.3B | -44.52% | +39.72% | $9.2K | -0.57% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 465 | $19.83 | $1.3B | -44.52% | +39.72% | $9.2K | -0.57% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 485 | $19.83 | $1.3B | -44.52% | +39.72% | $9.6K | -0.29% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 485 | $19.83 | $1.3B | -44.52% | +39.72% | $9.6K | -0.29% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | John E Davis | Chief Commercial Officer | 584 | $19.83 | $1.3B | -44.52% | +39.72% | $11.6K | -0.36% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | John E Davis | Chief Commercial Officer | 584 | $19.83 | $1.3B | -44.52% | +39.72% | $11.6K | -0.36% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | James P Mackin | President & CEO | 4,837 | $19.83 | $1.3B | -44.52% | +39.72% | $95.9K | -0.69% | — | Buy Now |
| Feb 27, 2024 | Sell | AORT | James P Mackin | President & CEO | 4,837 | $19.83 | $1.3B | -44.52% | +39.72% | $95.9K | -0.70% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Florian Tyrs | VP, Global Operations | 893 | $20.27 | $1.3B | -44.52% | +39.72% | $18.1K | -3.92% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 2,134 | $20.27 | $1.3B | -44.52% | +39.72% | $43.3K | -0.78% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 2,166 | $20.27 | $1.3B | -44.52% | +39.72% | $43.9K | -0.80% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Matthew A Getz | VP, Human Resources | 2,280 | $20.27 | $1.3B | -44.52% | +39.72% | $46.2K | -2.57% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Rochelle L. Maney | VP, Quality | 2,282 | $20.27 | $1.3B | -44.52% | +39.72% | $46.3K | -2.65% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Matthew A Getz | VP, Human Resources | 2,313 | $20.27 | $1.3B | -44.52% | +39.72% | $46.9K | -2.60% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Rochelle L. Maney | VP, Quality | 2,315 | $20.27 | $1.3B | -44.52% | +39.72% | $46.9K | -2.69% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Andrew M Green | VP Regulatory | 2,367 | $20.27 | $1.3B | -44.52% | +39.72% | $48.0K | -2.76% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Andrew M Green | VP Regulatory | 2,403 | $20.27 | $1.3B | -44.52% | +39.72% | $48.7K | -2.80% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 2,838 | $20.27 | $1.3B | -44.52% | +39.72% | $57.5K | -0.87% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 2,880 | $20.27 | $1.3B | -44.52% | +39.72% | $58.4K | -0.89% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 3,007 | $20.27 | $1.3B | -44.52% | +39.72% | $61.0K | -1.91% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | Marshall S. Stanton | SVP, Clinical & MD Affair | 3,048 | $20.27 | $1.3B | -44.52% | +39.72% | $61.8K | -1.94% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | John E Davis | Chief Commercial Officer | 3,461 | $20.27 | $1.3B | -44.52% | +39.72% | $70.2K | -1.09% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | John E Davis | Chief Commercial Officer | 3,514 | $20.27 | $1.3B | -44.52% | +39.72% | $71.2K | -1.11% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | James P Mackin | President & CEO | 30,836 | $20.27 | $1.3B | -44.52% | +39.72% | $625.1K | -2.24% | — | Buy Now |
| Feb 26, 2024 | Sell | AORT | James P Mackin | President & CEO | 31,312 | $20.27 | $1.3B | -44.52% | +39.72% | $634.7K | -2.27% | — | Buy Now |
| Feb 20, 2024 | Sell | AORT | Florian Tyrs | VP, Global Operations | 249 | $18.86 | $1.3B | -44.52% | +39.72% | $4.7K | -1.51% | — | Buy Now |
| Feb 20, 2024 | Sell | AORT | Rochelle L. Maney | VP, Quality | 407 | $18.86 | $1.3B | -44.52% | +39.72% | $7.7K | -1.38% | — | Buy Now |
| Feb 20, 2024 | Sell | AORT | Matthew A Getz | VP, Human Resources | 1,695 | $18.86 | $1.3B | -44.52% | +39.72% | $32.0K | -2.85% | — | Buy Now |
| Feb 20, 2024 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 1,695 | $18.86 | $1.3B | -44.52% | +39.72% | $32.0K | -0.69% | — | Buy Now |
| Feb 20, 2024 | Sell | AORT | John E Davis | Chief Commercial Officer | 2,556 | $18.86 | $1.3B | -44.52% | +39.72% | $48.2K | -0.99% | — | Buy Now |
| Feb 20, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 3,527 | $18.86 | $1.3B | -44.52% | +39.72% | $66.5K | -0.88% | — | Buy Now |
| Feb 20, 2024 | Sell | AORT | James P Mackin | President & CEO | 131,294 | $17.70 | $1.3B | -44.52% | +39.72% | $2.3M | -0.57% | — | Buy Now |
| Jan 2, 2024 | Sell | AORT | John E Davis | Senior VP, Global Sales | 27,124 | $17.15 | $1.3B | -44.52% | +39.72% | $465.2K | +0.00% | — | Buy Now |
| Jan 2, 2024 | Sell | AORT | Jean F Holloway | SVP, General Counsel | 42,458 | $17.15 | $1.3B | -44.52% | +39.72% | $728.2K | +0.00% | — | Buy Now |
| Dec 15, 2023 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 28,794 | $17.65 | $1.3B | -44.52% | +39.72% | $508.2K | +0.00% | — | Buy Now |
| Dec 6, 2023 | Buy | AORT | Amy Horton | VP, Chief Accounting Officer | 20,191 | $17.83 | $1.3B | -44.52% | +39.72% | $360.0K | +19.44% | — | Buy Now |
| Dec 6, 2023 | Buy | AORT | Lance A Berry | Executive VP, CFO | 42,064 | $17.83 | $1.3B | -44.52% | +39.72% | $750.0K | +44.92% | — | Buy Now |
| Nov 27, 2023 | Sell | AORT | Amy Horton | VP, Chief Accounting Officer | 3,851 | $17.42 | $1.3B | -44.52% | +39.72% | $67.1K | -1.81% | — | Buy Now |